CaRi-Heart Coronary Inflammation AI

Caristo Diagnostics Ltd. is a cardiovascular AI company with press release datelines in Oxford, England and Stamford, Connecticut. It commercializes technology based on more than a decade of research by co-founders at the University of Oxford.

CaRi-Heart analyzes routine coronary CT angiography images, using AI to quantify inflammation-related changes in the fat around the coronary arteries as the FAI-Score, and combines it into a 10-year cardiovascular mortality risk estimate. CaRi-Plaque adds quantitative plaque analysis. Both are offered to hospitals and imaging centers, and the technology is available in Europe, Switzerland, the UK and Australia.

• FAI-Score: Quantifies coronary inflammation from perivascular fat on CCTA.
• CaRi-Heart Risk: Estimates 10-year cardiovascular mortality risk.
• CaRi-Plaque: Provides quantitative plaque analysis from CCTA.
• Individualised risk score: Combines imaging biomarkers into patient-level risk.
• Core lab services: Supports pharma trials with imaging endpoints.

Cardiac imaging centers in Vietnam can add inflammation scoring to existing CCTA reports. Preventive cardiology clinics can refine statin decisions. Research hospitals can use imaging biomarkers in cardiovascular studies.

Extracts new risk information from CT angiograms already performed, with no extra scan.

Quantifies coronary inflammation, which standard CCTA or calcium scoring does not measure directly.

Provides a 10-year cardiovascular mortality risk score to guide prevention.

Holds FDA De Novo (CaRi-Heart), FDA 510(k) (CaRi-Plaque), CE and UKCA marks.

Coronary CT angiography use is rising and about half of first heart attacks occur in people rated low-risk by traditional tools, according to the company's release. Vietnam's growing CT capacity in major hospitals creates a base for imaging-derived risk tools.

Oxford, England and Stamford, Connecticut; CEO Stephen Deitsch appointed April 2026. CaRi-Heart FDA De Novo DEN250042 (July 2026); CaRi-Plaque FDA 510(k) K242240. AMA CPT Category III codes effective January 2026. Validation published in The Lancet.